Clinical Trial

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Study acronym: TRIUMPH-9
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-10
Trial Details
NCT Number NCT07357415
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight
Enrollment 600 participants
Start Date 2026-01-24
Primary Completion 2028-10 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-09